By Robert King
Some labs are starting to reach capacity for COVID-19 testing as several states reach record-level cases of the virus.
read more
By Arlene Weintraub
Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, reported researchers from Columbia University and the University of Wisconsin-Madison. What's key is their ability to disrupt a protein called polymerase.
read more
By Robert King
Senators pressed the Trump administration to put out a plan on how to distribute a vaccine and combat mistrust among the public to vaccines.
read more
By Angus Liu
Meeting global demand for a potential COVID-19 treatment is more than any one company can handle on its own. For Fujifilm, it has signed on India’s Dr. Reddy’s Laboratories and Dubai-based Global Response Aid to manufacture and sell its flu drug Avigan for potential treatment of COVID-19.
read more
By Robert King
Hospital financial losses are expected to continue through the rest of the year due to COVID-19, with an AHA analysis estimating losses of $120 billion from July through December.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Pfizer and BioNTech posted early data showing their mRNA vaccine candidate generated promising antibody levels in COVID patients. Plus, researchers from Columbia University and the University of Wisconsin-Madison identified five FDA-approved drugs that could halt the virus' spread. An analyst took issue with FDA's vaccine guidance. And more.
read more
By Eric Sagonowsky
In reviewing potential COVID-19 vaccines, FDA commissioner Stephen Hahn has pledged to "not cut corners" or allow politics to affect decision-making. But while the agency has laid out clear efficacy requirements for a full approval, its emergency use authorization pathway isn't so clear, GlobalData says.
read more
By Ben Adams
Nearly 200 companies have stopped or delayed their trials over the pandemic, and life science analytics firm GlobalData has dug into the data and found the main culprit has been suspended enrollment.
read more
